Sucampo Pharmaceuticals, Inc.
(NASDAQ : SCMP)

... ...
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 2.71%170.480.7%$1278.24m
PFEPfizer Inc. 0.07%37.310.9%$1194.50m
LLYEli Lilly & Co. 0.31%213.001.1%$1020.03m
ABBVAbbVie, Inc. -1.53%108.811.9%$749.27m
AZNAstraZeneca Plc 0.80%54.441.2%$709.95m
MRKMerck & Co., Inc. -1.06%80.290.7%$700.46m
BMYBristol-Myers Squibb Co. -0.60%64.441.0%$698.52m
ARCTArcturus Therapeutics Holdings, Inc. -6.41%64.990.0%$222.82m
VTRSViatris, Inc. -0.81%17.090.0%$196.54m
RPRXRoyalty Pharma Plc 2.56%52.820.2%$185.48m
NVSNovartis AG -2.60%95.910.2%$184.97m
GSKGlaxoSmithKline Plc 0.82%39.240.2%$163.38m
GRTSGritstone Oncology, Inc. -13.83%20.560.0%$162.66m
SNYSanofi -0.97%49.150.2%$137.60m
TAKTakeda Pharmaceutical Co., Ltd. -0.98%18.190.0%$80.46m

Company Profile

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.